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Abstract
Prions cause transmissible infectious diseases in humans and animals and have been
found to be transmissible by blood transfusion even in the presymptomatic stage. However,
the concentration of prions in body fluids such as blood and urine is extremely low; therefore,
direct diagnostic tests on such specimens often yield false-negative results. Quantitative
preanalytical prion enrichment may significantly improve the sensitivity of prion assays by
concentrating trace amounts of prions from large volumes of body fluids. Here, we show
that beads conjugated to positively charged peptoids not only captured PrP aggregates
from plasma of prion-infected hamsters, but also adsorbed prion infectivity in both the symp-
tomatic and preclinical stages of the disease. Bead absorbed prion infectivity efficiently
transmitted disease to transgenic indicator mice. We found that the readout of the peptoid-
based misfolded protein assay (MPA) correlates closely with prion infectivity in vivo, thereby
validating the MPA as a simple, quantitative, and sensitive surrogate indicator of the pres-
ence of prions. The reliable and sensitive detection of prions in plasma will enable a wide
variety of applications in basic prion research and diagnostics.
Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are caused by conforma-
tional transitioning of the physiological host-encoded prion protein, PrPC, into a misfolded
and aggregated form, PrPSc that accumulates in the brain in the form of plaques or smaller pla-
que-like deposits [1, 2]. PrPSc differs from PrPC in several biochemical and physicochemical
properties such as its insolubility and partial resistance to proteinase K [1].
Prion diseases are prevalent in several animals and in humans. In humans, prion diseases
can either appear spontaneously [3], be inherited [4] or acquired by infection [5–7] and
include Creutzfeldt-Jakob disease, Gerstmann-Stra¨ussler-Scheinker syndrome, fatal familial
insomnia and Kuru. In the late 1990s a new form of CJD, designated variant CJD (vCJD) has
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emerged, which was traced to the transmission of prions to humans from cattle afflicted with
BSE (bovine spongiform encephalopathy). The occurrence of vCJD indicated that BSE prions
have overcome the species barrier between cattle and humans [8–11]. The possibility of the
transmission of prions via blood was demonstrated by four confirmed fatal cases of vCJD in
the UK that were acquired by blood transfusion [12, 13]. Moreover, studies performed in
rodents, sheep and deer, additionally showed that prions can be efficiently transmitted via
whole blood transfusion as well as buffy coats from animals in the preclinical and clinical
stages of the disease [14–16].
The concentration of prions in blood, however, is low. In hamsters, where it has been stud-
ied in detail, it reaches at most 10 LD50 units per ml blood (LD50 represents the lethal dose
where 50% of the animals inoculated with prions come down) [17, 18]. In addition, blood frac-
tions from a single vCJD affected patient indicated an infectious titer of about 4.45 ID per mL
[19]. Moreover, infectivity titers around the detection limit were found in the plasma of mice
in the preclinical stage that have been infected with a mouse-adapted strain of human TSE
[20].
This fact has made it difficult to utilize conventional transmission bioassays for detecting
the presence of prion infectivity and has significantly hampered the validation of industrial
procedures for prion removal from blood products. Assays that are based on in vitro amplifica-
tion steps to increase the amount of detectable prions were developed [21, 22]. Efficient ampli-
fication and detection of PrPSc from the blood of hamsters infected with scrapie in the
presymptomatic stage was demonstrated with the protein misfolding cyclic amplification
(PMCA) assay [23]. More recently, the real-time quaking-induced conversion assay was devel-
oped, which amplifies PrPSc from tissue, cerebrospinal fluid (CSF), and other biological fluids
[24, 25]. However, assays that are based on amplification steps are time-consuming and not
well suited for automation and high-throughput screening applications. Also, assays that do
not rely on the use of proteinase K (PK), which significantly reduces the total amount of aggre-
gates available for detection, should allow for more sensitive detection of prions in body fluids
such as blood.
An assay without additional amplification steps and PK digestion is the misfolded protein
assay (MPA) [26–30]. The principle of the assay is based on a capturing step using magnetic
peptoid-conjugated beads (PSR1) [26, 30, 31] that avidly and selectively bind to prion aggre-
gates followed by quantification in an enzyme-linked immunosorbent assay (ELISA). PSR1
beads consist of magnetic beads conjugated with peptoides, which are peptidomimetics with
poly-N-substituted glycines [30]. This modification makes the peptoides highly resistance to
proteolytic digestion and applicable for the use in body fluidics that contain high amounts of
proteases [31, 32]. The sequence of the peptoide mimics the first eight residues of the mature
prion protein, KKRPKPGG. Those residues have been demonstrated to bind highly selectively
to prion aggregates [26, 31]. The detection of the MPA avails on the use of the dissociation of
the aggregates into monomers, thus increasing the number of available molecules and epitopes
for detection in the immunoassay [30, 31]. The readouts were also found to correlate well with
prion infectivity [33], suggesting that PSR1 beads physically capture prion seeds. Moreover,
the MPA was able to detect PrPSc, which was otherwise undetectable by proteinase K western
blot analysis in the brain of a patient with familial CJD [27].
To further evaluate the reliability and sensitivity of the MPA for the detection of prion
infectivity, we investigated in the present study the efficiency of PSR1 beads to capture prion
infectivity from the plasma of hamsters that were in the presymptomatic and symptomatic
stages of the disease. Additionally, we studied their efficiency to transmit disease to transgenic
hamster indicator mice.
Magnetic bead prion blood capture assay
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Materials and methods
Animal experimentation, animal welfare and ethics statement
All experiments with hamster were performed at Novartis Diagnostics, Emeryville, USA in
accordance with their animal welfare policies. All procedures involving hamsters were
approved and in compliance with the Guide for the Care and Use of Laboratory Animals by
the Institutional Animal Care and Use Committee of Novartis Diagnostics, Emeryville, USA.
All mice experiments were conducted in strict accordance with the Rules and Regulations for
the Protection of Animal Rights (Tierschutzgesetz and Tierschutzverordnung) of the Swiss
Bundesamt fu¨r Lebensmittelsicherheit und Veterina¨rwesen BLV. All protocols and experi-
ments performed with mice, were specifically approved for this study by the responsible insti-
tutional animal care committee, namely the Animal Welfare Committee of the Canton of
Zu¨rich (permit number 130/2008). Mice and hamster were maintained under conventional
conditions with 12h day/light cycles and all efforts were made to minimize animal discomfort
and suffering. Mortality of hamster and mice that occurred outside of planned euthanasia or
humane endpoints are summarized in S5 Table.
Generation of PSR1 beads
The PSR1 beads were generated by chemical conjugation of a thiolated PSR1 peptoid deriva-
tive to magnetic beads (Dynabeads™ M-270 Carboxylic Acid, Invitrogen, Carlsbad CA) as
described previously [30] and were provided as a 30 mg/ml suspension of beads in bead stor-
age buffer (1xPBS with 0.1% Sodium Azide, 0.01% Triton X-100). The PSR1 peptoid loading
on the beads was measured by quantitative ninhydrin assay to be 9.88 nmol/mg of beads.
Injection of PSR1 beads into tga20 mice
12 μl or 120 μl of PSR1 beads (3 μl or 30 μl beads/mouse for groups of 4 mice) were incubated
overnight with brain homogenate from healthy CD1 (wt) mice (Harlan Laboratories, Nether-
lands). Unbound material was removed by washing five times with 1 ml PBS. Beads were
resuspended in 120 μl PBS and inoculated intracerebrally (i.c.) into tga20 mice under
methoxyflurane anesthesia. Tga20 mice (6–8 weeks old), overexpressing the mouse prion pro-
tein [34], were randomly assigned into 2 groups: 3 mice were inoculated i.c. with 3 μl beads in
a total volume of 30 μll/mouse and 4 mice with 30 μl beads/mouse. After 31 days post inocula-
tion (dpi), mice were sacrificed under methoxyflurane anesthesia and histopathologically
examined for bead accumulation and toxicity. Mice were monitored 3 times per week in accor-
dance to the guidelines of the Animal Welfare Committee of the Canton of Zu¨rich.
Preparation of hamster plasma
Golden Syrian hamsters (n = 40) at one-month weanling stage were anesthetized with 3% iso-
fluorane/L O2 and inoculated intraperitoneally (i.p.) with 100 μl of 1% (w/v) 263K hamster
prion strain infected hamster brain homogenate (estimated at 107 LD50 infectious units) using
the technique outlined by Laursen and Belknap [35, 36]. Control hamsters (n = 5) were inocu-
lated with 100 μl of a 1% non-infectious hamster brain homogenate. Blood was harvested from
the hamsters at the presymptomatic stage (30, 50 and 80 dpi) and at the symptomatic stage
(104–106, 117–118, 143, 154 dpi). Plasma was obtained as described previously [37]. Briefly,
hamsters were anesthetized with 3% isofluorane/L O2 and blood was taken in the presence of
EDTA-anticoagulant by cardiac puncture at various time points. Individual blood samples
were centrifuged at 950xg for 10 minutes and the plasma in the supernatant fraction was
Magnetic bead prion blood capture assay
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transferred to another tube and frozen at -80˚C. The clinical assessment and actions to mini-
mize animal suffering and distress were performed as summarized in S4 Table.
Bead-based capture of PrPSc
For the sensitivity assay, groups of Tg(SHaPrP) mice (6–8 weeks old; n = 4–8; randomly
assigned) were inoculated i.c. with 30 μl of serial ten-fold dilutions of a 263K-infected 10%
brain homogenate in PBS under methoxyflurane anesthesia [38]. For the PSR1 capture assay,
the plasma from 20 pre-symptomatic hamsters at 30 dpi, from 20 pre-symptomatic hamsters
at 50 dpi, from 14 symptomatic hamsters at 104–106 dpi, from 15 symptomatic hamsters at
117–118 dpi, from 11 symptomatic hamsters at 143 and 154 dpi, and from 2 non-infected
hamsters at 80 days inoculated with PBS were combined to individual pools. 21 μl of PSR1
beads were washed five times in 1 ml PBS (8 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl,
2.7 mM KCl, pH7.4) before incubation with 500 μl of pooled hamster plasma overnight at 4˚C
upon shaking. Beads were again washed five times with 1 ml of PBS or TBSTT to remove
unbound material and resuspended in 60 μl or 120 μl PBS, respectively. Groups of Tg(SHaPrP)
mice (6–8 weeks old; n = 4–8, randomly assigned) were inoculated i.c. with 30 μl resuspended
beads under methoxyflurane anesthesia.
For the analysis of the bead location in a tga20 mouse inoculated with RML6-coated PSR1
beads, groups of tga20 mice (6–8 weeks old; n = 4–8) were inoculated i.c. under methoxyflu-
rane anesthesia with PSR1 beads treated with 10% RML6 brain homogenate ranging from 10−2
to 10−10 overnight as previously described [33]. The clinical assessment and actions to mini-
mize animal suffering and distress were performed as laid out in S4 Table and as described pre-
viously [39].
Histopathology and immunohistochemical stains
Two-μm thick sections were cut onto positively charged silanized glass slides and stained with
hematoxylin and eosin (HE) or immunostained using antibodies for PrP (SAF84), astrocytes
(glial fibrillary acidic protein, GFAP) and microglia (IBA-1). For PrP staining, sections were
deparaffinized and incubated for 6 min in 98% formic acid, then washed in distilled water for
5 min.
Sections were heat-treated and immunohistochemically stained on an automated NEXES
immunohistochemistry staining apparatus (Ventana Medical Systems, Switzerland) using an
IVIEW DAB Detection Kit (Ventana). After incubation with protease 2 (Ventana) for 16 min,
sections were incubated with anti-PrP SAF-84 (SPI bio; 1:200) for 32 min. Sections were coun-
terstained with hematoxylin. GFAP immunohistochemistry for astrocytes (rabbit anti–mouse
GFAP polyclonal antibody 1:13000 for 24 min; DAKO) and IBA-1 for microglia (rabbit poly-
clonal antibody 1:1000 for 24 min, WAKO) was similarly performed.
Histoblot analysis was performed using a modified standard protocol according to [40].
Briefly, 10 μm thick cryosections were mounted on glass slides and immediately pressed to a
Nitrocellulose membrane (Protran, Schleicher & Schuell), soaked with lysis buffer (10 mM
Tris-HCl, 100 mM NaCl, 0.05% Tween 20, pH 7.8) and air dried. After protein transfer, sec-
tions were rehydrated in TBST for 1 hour previous to Proteinase K digestion with 20, 50 and
100 μg/ml in 10 mM Tris-HCl pH 7.8 containing 100 mM NaCl and 0.1% Brij35), for 4 hours
at 37 ˚C. After washing the membrane 3 times in TBST, a denaturation step with 3 M Guanidi-
nium thiocyanate in 10 mM Tris-HCl, pH 7.8 was performed for 10 min at room temperature.
The membrane was washed and blocked with 5% non-fat milk (in TBST) and incubated with
anti-PrP antibody POM-1 (epitope in the globular domain, aa 121–231), 1:10000, overnight at
4 ˚C [41]. The blots were washed again and an alkaline-phosphate-conjugated goat anti mouse
Magnetic bead prion blood capture assay
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antibody was added (DAKO, 1:2000). Another washing step with TBST and B3 buffer (100
mM Tris, 100 mM NaCl, 100 mM MgCl2, pH 9.5) was followed by the visualisation step with
BCIP/NBT (Roche) for 45 minutes. The colour development step was stopped with distilled
water. Blots were air-dried and pictures were taken with an Olympus SZX12 Binocular and
Olympus Camera.
Immunoblotting
10% brain homogenates were prepared in 0.32 M sucrose by using a Precellys24 (Bertin).
Extracts of 50–90 μg protein were digested with 50 μg/ml proteinase-K in DOC/NP-40 0.5%
for 45 minutes at 37˚C. The reaction was stopped by adding 3 μl complete protease inhibitor
cocktail (7x concentrated) and 8 μl of a lauryl dodecyl sulfate (LDS)-based sample buffer. The
samples were heated to 95˚C for 5 minutes prior to electrophoresis through a 12% Bis-Tris
precast gel (Invitrogen), followed by transfer to a nitrocellulose membrane by wet blotting.
Proteins were detected with anti-PrP POM-1 antibody (1:10000). For secondary detection, an
HRP-conjugated anti-mouse IgG antibody (Zymed, Invitrogen) was used and signals were
visualized with an ECL detection kit (Pierce).
Statistical evaluation
Results are expressed as the mean ± standard deviation (SD) as indicated.
Results
Assessment of bead toxicity
We first evaluated in a pilot experiment, whether peptoid-conjugated beads exposed to brain
homogenates from healthy wild-type CD1 mice would induce any acute toxic response in
recipient mice (Table 1). 3 μl or 30 μl beads, respectively, from a 30 mg/ml suspension of beads
were incubated overnight with the brain homogenate and inoculated i.c. into groups of 3 and
4 tga20 mice, respectively, overexpressing the mouse prion protein [42]. All mice were sacri-
ficed at 31 days, except for one mouse that had already died at 8 dpi, and subsequently analysed
for acute toxicity and bead accumulation. Beads were detectable only at the injection site in the
brain of the mouse, that had died at 8 dpi, (Fig 1A, S1 Fig), whereas in the remaining mice they
were found to be broadly distributed in both hemispheres. Beads were often observed to be
grouped in small clusters and were more abundant in intra- and periventricular regions,
including the corpus callosum, ependymal lining, choroid plexus as well as the leptomeninges
(Fig 1B–1E, S2 and S3 Figs). Mild gliosis and microglial activation were observed around the
injection site at 8 dpi (Fig 1A), while a more diffuse astrogliosis was observed at 31 dpi
(Fig 1B–1E, S2 and S3 Figs). Gliosis, which is a nonspecific reaction to injury in the central
nervous system [43], was more pronounced in the hippocampus, deep gray nuclei, medial
habenular nucleus, brainstem and deep cerebellar white matter. As the lateral ventricles did
not show evidence of hydrocephalus, we conclude that the beads did not significantly disturb
the outflow of the cerebrospinal fluid (S1 Fig).
Table 1. Pilot experiment: Assessment of bead toxicity in tga20.
PSR1 beads, coated with healthy brain homogenate Total inoculated Sacrificed at
3 μl beads in 30 μl PBS/mouse 3 31, 31, 31 dpi
30 μl in 30 μl PBS beads/mouse 4 8�, 31, 31, 31 dpi
�Mouse died of an intercurrent death.
https://doi.org/10.1371/journal.pone.0216013.t001
Magnetic bead prion blood capture assay
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Fig 1. Histopathological analysis of tissue reactions to intracerebral bead inoculation. Tga20 mice were inoculated with PSR1
beads that had been exposed to wt CD1 brain homogenates. Vacuolation by hematoxylin-eosin staining (HE), astrocytic gliosis
was documented by an antibody directed against the glial fibrillary acidic protein (GFAP), and microgliosis was assessed with the
activated microglial marker (Iba-1). (A) Brain sections of a tga20 mice analysed at 8 dpi showed bead accumulation near the
injection site. (B) Brain sections analyzed at 31 dpi showed accumulation of the beads adjacent to the corpus callosum, (C)
choroid plexus and (D) lateral ventricle, and in the area between corpus callosum and the septofimbrial nucleus (E). (Scale bars:
100 μm).
https://doi.org/10.1371/journal.pone.0216013.g001
Magnetic bead prion blood capture assay
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End-point titration of the 263K hamster strain in Tg(SHaPrP)
10-fold serial dilutions (10−2 to 10−12) of a 10% (w/v) 263K hamster brain homogenate were i.
c. inoculated into groups of 4 to 8 Tg(SHaPrP) mice, overexpressing the wild-type hamster
prion protein [38] (Fig 2A, Table 2). Clinical signs were observed in mice inoculated with dilu-
tions spanning 10−2 to 10−9 after mean incubation periods between 40 and 107 days (Fig 3,
Table 2). A standard calibration curve for the infectivity of the 263K hamster strain in Tg
(SHaPrP) was generated and a median 50% lethal dose [LD50] of 10
9.23 units ml-1 was calcu-
lated using the Reed-Muench formula [44–47].
Bioassay in Tg(SHaPrP) mice of PSR1 beads treated with plasma from
prion infected hamster
Next, we determined in a bioassay in Tg(SHaPrP) transgenic mice, whether the PSR1 beads
were able to capture quantitatively prion infectivity from plasma samples. To that purpose, we
used pools of plasma from 263K prion-infected hamster at presymptomatic or symptomatic
stages. Plasma samples from symptomatic hamsters were collected at the stage of onset of clini-
cal signs showing the typical disease characteristics of ataxia, loss of appetite and poor groom-
ing. The individual pools (Table 3) were incubated overnight with the PSR1 beads. After an
intense washing step, the beads were i.c. inoculated into Tg(SHaPrP) mice [38]. None of the
mice inoculated with PSR1 beads coated with plasma from presymptomatic hamsters (30 dpi)
nor any of the negative control mice showed any clinical signs of a prion disease. However,
two mice (n = 4) inoculated with beads incubated with plasma from a presymptomatic hamster
(50 dpi) developed disease with highly variable incubation periods after 56 and 85 dpi (equiva-
lent to an apparent ID50 of 3.2 ± 2.2 units ml-1 of 30 μl 10% 263K hamster brain homogenate,
Fig 2B, Table 3) and incomplete attack rate.
Most other mice inoculated with beads treated with the different plasma pools from symp-
tomatic hamster showed mean incubation periods between 74 ± 3 and 94 ± 5 dpi (equivalent
to apparent ID50’s of 2.8 ± 0.3 to 1.9 ± 0.5 units ml-1 Fig 2B, Table 3). The incubation times
within the transgenic mouse bioassay increased with the use of inoculums obtained from
symptomatic hamster with longer incubation times. The longest incubation time in the indica-
tor mice was observed for the pooled inoculum derived from symptomatic hamster sacrificed
at days 143 dpi and 154 dpi. This group of mice also exhibited a lower attack rate of 81%.
The calculated titers are slightly higher than the apparent titer of 1.25 LD50 ml
-1, estimated
from the quantity of 10 LD50 ml
-1 infectivity found in the blood of hamsters during the symp-
tomatic stage of the disease [17, 48], for 30 μl resuspended PSR1 beads coated with plasma
from prion-infected hamster. Histopathological and immunohistochemical analysis of the
brains of the mice was used to diagnostically confirm the presence for a prion disease (Fig 3).
Additionally, PK resistant PrP, a surrogate marker of prion disease, could be detected by histo-
blot and Western blot analyses (Figs 3 and 4). We therefore conclude that PSR1 beads highly
efficiently capture prion infectivity from plasma from presymptomatic and symptomatic cases
and are able to transmit infectivity to Tg(SHaPrP) mice.
Mice were also analyzed after termination for the location of the beads. After 90 dpi, beads
were mostly found in the brain, spinal cord and CSF, but also in most other organs (if only in
small numbers) as well as in urine and feces (see S1–S3 Tables). After 250 dpi, only a few beads
were observed in the brain with occasional beads around the spinal cord, in the spleen and in
selected other organs (see S1–S3 Tables). A similar distribution of the beads was also observed
in tga20 mice i.c. inoculated with PSR1 beads treated with a 10−9 dilution of a 10% (w/v)
RML6 brain homogenate and sacrificed at 253 dpi (S4 Fig, [33]). These data indicate that
beads might have been transported along the axonal route [49] or lymphatics [50, 51].
Magnetic bead prion blood capture assay
PLOS ONE | https://doi.org/10.1371/journal.pone.0216013 September 12, 2019 7 / 18
Fig 2. Survival plots of tg(SHaPrP) mice. (A) For titer determination, tg(SHaPrP) mice were inoculated with serial
10-fold dilutions of a 10% (wt/vol) 263K hamster brain homogenate ranging from 10−2 to 10−12. (B) Bioassay of Tg
(SHaPrP) mice that were inoculated i.c. with PSR1 beads incubated with pooled plasma samples from hamsters
infected with 263K prions. Individual pools of plasma samples from pre-symptomatic hamsters harvested at 30
(n = 20) and 50 dpi (n = 20) and from symptomatic hamsters harvested at 104–106 dpi (n = 14), 117–118 dpi (n = 15),
and 143 and 154 dpi (n = 11) were used. Data points: mean incubation times ± standard error of the mean. Mice that
did not develop a prion disease until the end of the experiment are indicated by open circles. n/n˚: indicates the attack
rate (number of mice developing a prion disease divided by the total number of inoculated mice). Ø80: indicates the
control group of mice inoculated with PSR1 beads after incubation with plasma from healthy 80 days old hamsters
(n = 2).
https://doi.org/10.1371/journal.pone.0216013.g002
Magnetic bead prion blood capture assay
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Discussion and conclusion
Previously, we have reported that the MPA could detect prion aggregates with high sensitivity
in the brain of a patient with a familial prion disease [27]. Crucially, the MPA detected PK sen-
sitive conformers of PrPSc that were only barely detectable by standard methods [27]. The ana-
lytical sensitivity of the MPA has recently been determined in a spiking experiment of a BH
from a vCJD patient into normal human plasma. PrP aggregates were still detectable at a dilu-
tion below 10 nl/ml (10−6 dilution, LOD estimated to be< 40 pg/ml of aggregated PrP) [31].
These findings prompted us to investigate further the sensitivity of the peptoid-conjugated
beads to capture prion infectivity from the plasma of prion-infected hamsters. This is biologi-
cally and medically relevant because (1) the conformation of infectious PrP in blood is
unknown and (2) the detection of prions in blood and blood products continues to represent a
major analytical challenge.
Our data showed that the PSR1 beads were able to enrich low concentrations of infectivity
from the plasma of hamsters in symptomatic and even presymptomatic stages of the disease.
Although we have not performed a direct injection of plasma pools from 263K prion-infected
hamster at presymptomatic or symptomatic stage to estimate the infectivity titers, our findings
suggest that the beads are capable of capturing prion infectivity from plasma at concentrations
around the threshold of detection identified earlier in rodent prion infectivity experiments for
presymptomatic cases [17, 18]. Alternatively, the high capture efficiency of PSR1 beads could
stem from an ability to detect more PK sensitive conformations of PrPSc, as prions in plasma
were proposed to consist of more PK sensitive conformations of PrPSc [52]. The apparent
higher titers of PrPSc on the bead surfaces might also be caused from PrPSc being protected
against degradation on the bead, e.g. by limiting exposure to proteolysis.
Transmission of infectivity from solid-state surfaces might occur either by dissociation of
infectivity or by the transport of these surfaces to different brain areas where they initiate infec-
tion [53, 54]. We observed that the beads stayed at the injection site within the first days after
injection. After 31 days, the beads were found to be more diffusely distributed within the
brain, with a greater density in periventricular regions and within the leptomeninges. After 90
days, only a few beads could be detected, which were subsequently found in most organs and
Table 2. Summary of end-point titrations of the 263K inoculum in Tg(SHaPrP).
Dilution of brain homogenatea (Clinical TSE/total inoculated) Mean incubation period (days ± SD) [42, 47]
10−2 4/4 42 ± 1
10−3 4/4 47 ± 1.4
10−4 4/4 51 ± 0.5
10−5 4/4 56 ± 1.2
10−6 4/4 57 ± 3.3
10−7 4/4 79 ± 7.4
10−8 8/8 100 ± 34
10−9 5/8 83, 90, 90, 90, 107, >250, >250, >250
10−10 1/4 174b, >250, >250, >250
10−11 0/3 >247
10−12 0/2 >247
a Dilutions were started from a 10% brain homogenate.
b The incubation period to terminal disease was about 174 days at the end-point. An approximate linear regression
curve (y = 10.6–0.105x; r = 0.87) was calculated from the mean incubation periods of dilutions 10−2 to 10−9.
https://doi.org/10.1371/journal.pone.0216013.t002
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Fig 3. Pathology of hippocampus, medial habenular and thalamic nuclei from Tg(SHaPrP) mice. Non-inoculated mice (A)
show no evidence of vacuolation, PrPSc deposition or gliosis. Mice inoculated with 263K prion-infected hamster brain
homogenate (B), inoculated with PSR1 beads incubated with plasma pools from symptomatic hamster at 117–118 dpi (C) and at
143 and 154 dpi (D) show vacuoles in the HE stained section (see also S2 and S3 Figs), PrPc and PrPSc deposition as visualized by
the PrP antibody SAF84 and astrocytic gliosis as evidenced by an antibody directed against GFAP. Histoblot analysis was used to
show PrPSc deposition after proteinase K digestion and staining with POM1. (Scale bars: 1 mm).
https://doi.org/10.1371/journal.pone.0216013.g003
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body fluids. Possible routes of clearance include the internal and external veins that enter the
dural sinuses, and then eventually drain into the internal jugular veins. Other potential con-
duits for clearance are along axons [49] or recently described lymphatic vasculature that lines
dural sinuses in the meninges and drains into cervical lymph nodes [50, 51, 55].
Prions have been shown to form structurally distinct PrPSc conformers, known as prion
strains [56]. Those strains consist of different particle size distributions of prion aggregates
responsible for different biophysical properties that determine the course of the disease [57].
The size of the PrP aggregate might influence PSR1 avidity and impair the sensitivity of the
assay for strains composed of smaller prion aggregates. However, PSR1 beads were shown to
bind to a broad range of Abeta amyloidogenic aggregates, the key species in the pathology of
Alzheimer’s disease (AD) [58], with different conformations and of different sizes ranging
from at least <50 to>400 amino acids [30]. This gives evidence that PSR1 might bind sensi-
tively to a broad range of strains that are composed of aggregates of different size.
The ability of PSR1-coated beads to efficiently capture and enrich prions from plasma
directly suggests the feasibility of solid-state prion-capture matrices for both clinical and
research uses. For example, the beads might be applied for depletion, removal and clearance of
prions from biological fluids and biopharmaceutical products. The number of beads can easily
be increased and their magnetic properties should allow the capture of prions even in high vol-
umes. In a further embodiment, the beads might also be applied in concert with the scrapie
cell endpoint assay (SCEPA) [59] and/or with prion amplification assays, such as the PMCA
and RT-QuIC [60, 61]. Pre-analytical capture has recently been shown to improve the sensitiv-
ity of these assays by several orders of magnitude, enabling the sensitive and selective detection
of prions in blood and body fluidics from various species [59–61], including those from vCJD
patients [62, 63]. Different methods have been applied for pre-analytical capture, including the
capture with magnetic beads containing a Fe3O4 metal surface [60, 64], solid-state capture
matrices consisting of stainless steel [63] or magnetic plasminogen coated-beads [62, 65]. Mag-
netic Fe3O4 metal surface beads [60, 64] have been described to avidly bind to the metal-bind-
ing domains of aggregated PrP [66, 67]. Similarly, the avidly binding of stainless steel surfaces
to PrP aggregates is mediated by an interaction to nickel and molybdenum [68]; most properly
also induced by the metal-binding domains of PrP. Finally, the binding of plasminogen coated
Table 3. Summary of bioassays with Tg(SHaPrP) mice that were inoculated with plasma coated PSR1 beads.
Plasma Pools Attack rate
(Clinical TSE/total inoculated)
Mean incubation period (days) Estimated titers�
Log LD50 units ml
-1 [42, 47]
pre-symptomatic hamster, 20 animals, 30 dpi 0% (0/8) 8 survivor terminated at 322 dpi
pre-symptomatic hamster, 20 animals, 50 dpi 50% (2/4) 56 and 85 dpi (71 ± 21 dpi)
(plus 2 survivor terminated at 211
dpi)
3.2 ± 2.2
symptomatic hamster, 14 animals, 104–106 dpi 100% (8/8) 74 ± 3 dpi 2.8 ± 0.3
symptomatic hamster, 15 animals, 117–118 dpi 100% (4/4) 76 ± 5 dpi 2.4 ± 0.5
symptomatic hamster, 11 animals, 143 dpi and 154 dpi 81% (13/16) 94 ± 5 dpi
(plus 3 survivor terminated at 211
dpi)
1.9 ± 0.5
non-infected hamster, 2 animals, 80 days after PBS
inoculation
0% (0/2) 8 survivor terminated at 308 dpi
�Titers were estimated from the calibration curve of the end-point titrations of the 263K inoculum in Tg(SHaPrP) (Table 2; Fig 2) using the incubation time method.
https://doi.org/10.1371/journal.pone.0216013.t003
Magnetic bead prion blood capture assay
PLOS ONE | https://doi.org/10.1371/journal.pone.0216013 September 12, 2019 11 / 18
Fig 4. PK-Western blot analysis of brain homogenates from Tg(SHaPrP) mice inoculated with PSR1 beads coated
with plasma from symptomatic hamster. (A-C) PrPSc is present in Tg(SHaPrP) inoculated i.c. with PSR1 beads
incubated with plasma pools from symptomatic hamsters. Mice were incubated either with 5.25 or 10.5 μl of PSR1
beads in PBS (A) or in TBSTT (B-C). Because of the high expression level of PrPC in Tg(SHaPrP), PrPC is still
detectable on Western blots. Control samples are labeled with NBH: non-infected brain homogenate from healthy
mice, and 263K: brain homogenate from mice inoculated with 263K prions. BV: bead volume. The anti-PrP antibody
POM-1 was used for detection. The molecular weight standard is shown in kilodaltons.
https://doi.org/10.1371/journal.pone.0216013.g004
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magnetic nanobeads to PrP aggregates has been reported to be based on specific interactions
of the lysine binding site 1 of plasminogen [69]. The binding mode of these capture reagents
have in common with the one of the PSR1 beads that they are based on the property of PrP
aggregates to avidly bind to various surfaces using non-covalent binding interactions [53, 54].
The interaction of PSR1 beads to PrP aggregates relies on the cooperative binding of cationic
PSR1 residues to negatively charged PrP aggregates [26, 30, 31], whereas the interaction with
monomeric PrP is weak [26, 30, 31]. This allows the selective capture of PrP aggregates with an
about 4000-fold higher binding specificity for aggregated PrP over monomeric PrP [26]. Mul-
tivalent non-covalent interaction-based immobilization procedures therefore seem to be
highly suitable for the efficient capture and enrichment of PrP aggregates that are only present
at very low quantities in blood.
Finally, the PSR1 beads might also be used together with a sensitive detection method to
diagnose prions. Prion bioassays report the infectious titer and do not directly reflect the total
number of PrP molecules, whereas the MPA reports the amount of PrP in aggregated confor-
mations. Because each aggregate can be composed of a vast number of PrP molecules, the sub-
sequent disaggregation can lead to the exposure of many epitopes for sensitive
immunodetection. A sensitive prion detection assay based on the MPA technology could be
easily automatable and optimized for high-throughput applications, eventually paving the way
to early and sensitive blood diagnosis of prion diseases in humans and to the prevention of
transmission of prions through economical and reliable screening of blood and blood
products.
Supporting information
S1 ARRIVE. Guidelines checklist.
(PDF)
S1 Fig. Histopathological analysis of tissue reactions to intracerebral bead inoculation.
Coronal sections at low magnification show that the outflow of the CSF through the lateral
ventricles is not affected. (A) Brain sections of a tga20 mouse inoculated with PSR1-beads scar-
ified at 8 dpi. (B) Brain sections of a tga20 mouse inoculated with PSR1-beads and terminated
at 31 dpi. Vacuolation was again visualized by HE staining, astrocytic gliosis by staining the
GFAP protein with a GFAP-specific antibody, and microgliosis by the activated microglial
marker Iba-1. Activation of astrocytic gliosis and microgliosis was detected near the injection.
(Scale bars: 1 mm).
(TIF)
S2 Fig. Same as in Fig 3, but the pathology of sections of the hippocampus and corpus cal-
losum are shown at higher magnification to better visualize vacuolation. Non-inoculated
mice (A) show no evidence of vacuolation, PrPSc deposition or gliosis. Mice inoculated with
263K prion-infected hamster brain homogenate (B), inoculated with PSR1 beads incubated
with plasma pools from symptomatic hamster at 117–118 dpi (C) and at 143 and 154 dpi (D)
show vacuoles in the HE stained section, PrPc and PrPSc deposition is visualized by the PrP
antibody SAF84 and astrocytic gliosis is evidenced by an antibody directed against GFAP.
(Scale bars: 100 μm).
(TIF)
S3 Fig. Same as in Fig 3, but the pathology of sections of the thalamus are shown at higher
magnification to better visualize vacuolation. Non-inoculated mice (A) show no evidence of
vacuolation, PrPSc deposition or gliosis. Mice inoculated with 263K prion-infected hamster
brain homogenate (B), inoculated with PSR1 beads incubated with plasma pools from
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symptomatic hamster at 117–118 dpi (C) and at 143 and 154 dpi (D) show vacuoles in the HE
stained section, PrPc and PrPSc deposition is visualized by the PrP antibody SAF84 and astro-
cytic gliosis is evidenced by an antibody directed against GFAP. (Scale bars: 100 μm).
(TIF)
S4 Fig. Histopathological analysis of bead location in tissue sections from a tga20 mouse
inoculated with RML6-coated PSR1 beads. The mouse shown was inoculated with RML6
brain homogenate (10−9 dilution) and euthanized at 253 dpi. HE stained sections of brain,
spleen, spinal cord ganglion and spinal cord out nerve are shown. Beads are indicated with yel-
low arrows. (Scale bars: 50 μm).
(TIF)
S5 Fig. Uncropped and unmodified Western blots of Fig 4.
(TIF)
S1 Table. Location of PSR1 beads in body fluids from mice inoculated with 3 μl beads
coated with plasma from prion-infected hamster per mouse. Yes: beads were present in
these body fluids. No: no beads were observed. n.a.: non-analyzed. dpi: days post infection.
The analysis was only performed for the indicated mice.
(PDF)
S2 Table. Presence of PSR1 beads in various tissue homogenates from mice inoculated
with 3 μl beads coated with plasma from prion-infected hamster per mouse. Yes: beads
were found in these homogenates. No: no beads were observed. n.a.: non-analyzed. dpi: days
post infection. The analysis was only performed for the indicated mice.
(PDF)
S3 Table. Presence of PSR1 beads in various organs from mice inoculated with 3 μl beads
coated with plasma from prion-infected hamster per mouse. Paraffin sections of various
organs were analysed for the presence of the beads. Yes: beads were found in these organs. No:
no beads were observed. n.a.: non-analyzed.?: not clearly identified. BM: bone marrow. dpi:
days post infection. The analysis was only performed for the indicated mice.
(PDF)
S4 Table. Clinical assessment and scoring of Golden Syrian hamsters inoculated with the
263K hamster prion strain, tga20 mice inoculated with RML6, and Tg(SHaPrP) mice either
inoculated with 263K or with plasma coated PSR1 beads as described in [39]. Animals were
monitored 3 times per week after RML6 or 263K inoculation for clinical signs including gait,
grooming, activity, rough hair coat, limb paresis and ataxia. Once the animals showed the first
sign of scrapie (grade 1), they were monitored every day and wet food was supplied in the
cage. When the animals reached score grade 2 that hindered them reaching the water bottle,
they were either euthanized with 3% isofluorane/L O2 (hamster) or methoxyflurane (mice),
followed by decapitation.
(PDF)
S5 Table. Mortality of hamster and mice that occurred outside of planned euthanasia or
humane endpoints.
(PDF)
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